From Code to Cure®
Using a predictive computational platform to discover untapped drug targets and extend the reach of cancer immunotherapies to new patient populations
Pipeline
We are advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are refractory or unresponsive to currently available drugs


Computational Discovery
Our approach leverages the predictive power of our computational drug target discovery platform to discover novel drug targets
Clinical Trials
Our potentially first-in-class therapeutic antibodies targeting novel pathways are currently being evaluated in multiple clinical trials
Corporate Presentation
Our Triple Combination Approach
We believe that the PVRIG pathway we discovered is a potential paradigm shifting target to enhance patient responses to cancer immunotherapies and may provide new treatment options as monotherapy or in combination with other immune checkpoints to expand the reach of cancer immunotherapies to new patient populations.
News
Join Our Team
Join our team of leading research experts and drug developers that discover novel drug targets and develop treatments to extend the reach of immunotherapies
Publications
Compugen has received over 120 granted or pending patents and published over 80 peer reviewed publications